Clinical Trials

37 enrolled

Pancreatic Neoplasms

NCT07469306 2026-03-13

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

130 enrolled

Locally Advanced Rectal Cancer

NCT06787183 2026-03-03

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

42 enrolled

Locally Advanced Rectal Cancer With Liver Metastases

NCT06313801 2025-11-21

Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

106 enrolled

Stomach Neoplasms

NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

38 enrolled

Mid-low Rectal Cancer

NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3 Recruiting

269 enrolled

Stomach Neoplasms

NCT06888843 2025-03-27

AHTCRR-1

160 enrolled

Colorectal Neoplasms

NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

40 enrolled

Immunotherapy

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Phase 1/2 Recruiting

51 enrolled

Stomach Neoplasms

NCT06788171 2025-01-23

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

35 enrolled

Colorectal Cancer Liver Metastasis

NCT06490913 2024-07-08

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

33 enrolled

Liver Metastases of Colorectal Cancer

NCT05699655 2024-05-01

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Phase 2/3 Recruiting

130 enrolled

Phase 2 Active not recruiting

Immunotherapy Gastrict Cancer

NCT03950271 2024-02-28

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

25 enrolled

Stomach Neoplasms

NCT06197438 2024-01-09

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

36 enrolled

Stomach Neoplasms

NCT05839470 2023-11-15

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

20 enrolled

Colorectal Neoplasms

NCT05479240 2023-06-18

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

94 enrolled

Immunotherapy

NCT05640726 2022-12-07

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

30 enrolled

Rectal Neoplasms

NCT05608785 2022-11-08

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Phase 1/2 Unknown

45 enrolled

Stomach Neoplasms

NCT00070213 2021-09-27

Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer

Phase 3 Completed

460 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00640081 2021-09-22

Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer

169 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04351867 2020-07-16

A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer

Phase 3 Unknown

196 enrolled

Stomach Neoplasms

NCT03222089 2018-03-27

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Phase 2 Withdrawn

Colorectal Neoplasms

NCT03045770 2017-02-07

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Phase NA Unknown

150 enrolled

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

NCT01843829 2014-03-24

NeoSCOPE

85 enrolled

Esophageal Neoplasms

NCT00636883 2014-01-22

GEMOX-T

Phase 2 Terminated

9 enrolled

Pancreatic Neoplasms

NCT01331928 2011-04-08

Sequential Chemotherapy With Xelox Follows by TX to Treat Gastric Cancer

51 enrolled

Stomach Neoplasms

NCT00452881 2010-10-25

Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC

151 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00453115 2010-10-25

Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

43 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00512681 2009-09-18

TIROX2

44 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT00506207 2007-07-25

TIROX

Phase 1 Unknown

23 enrolled

Gastrointestinal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT00506571 2007-07-25

TIROX2

42 enrolled